New Global Evidence Reinforces Effectiveness of Romosozumab in Combating Osteoporosis
At the prestigious WCO-IOF-ESCEO 2025 congress in Rome, new international data have brought fresh momentum to the growing recognition of romosozumab as a highly effective dual-acting treatment for osteoporosis.
The treatment, known for both stimulating bone formation and reducing bone resorption, continues to reshape how clinicians approach the management of this widespread and debilitating condition.
A systematic literature review formed the backbone of the evidence presented, encompassing 362 records drawn from 67 studies across 10 countries.
The findings were striking: romosozumab demonstrated statistically significant improvements in bone mineral density (BMD) after 12 months, specifically in the lumbar spine, total hip, and femoral neck – key areas critical to mobility and quality of life.
Particularly notable were the greater gains in BMD seen in treatment-naïve patients compared to those with previous osteoporosis therapies.
A lead investigator involved in the research highlighted the importance of timely intervention. They stated that treating patients at high fracture risk with romosozumab at the right time plays a crucial role in strengthening bones and significantly reducing fracture risk, underscoring the urgency for appropriate early diagnosis and intervention.
UCB, the pharmaceutical company behind romosozumab, has also expanded the real-world evidence base with robust studies across Europe.
In Germany, a retrospective analysis revealed that patient costs remained stable during the first year of treatment, followed by a notable reduction in costs during the second year. These results point to romosozumab’s long-term cost-effectiveness – a critical factor in health policy and prescribing practices.
In Sweden, a national registry study revealed that 76.9% of romosozumab-treated patients were treatment-naïve, suggesting that the treatment is increasingly being embraced as a first-line option.
Meanwhile, a claims data analysis from Germany exposed concerning gaps in osteoporosis management, with many high-risk women left untreated, often resulting in preventable secondary fractures. These insights point to the need for better identification and timely treatment of at-risk patients.
Commenting on the latest findings, UCB’s Chief Commercial Officer expressed confidence in romosozumab’s growing reputation.
They expressed that the expanding body of real-world evidence reinforces their commitment to delivering meaningful benefits to patients and gives healthcare professionals the confidence they need in romosozumab’s impact.
Since its EU approval in December 2019 for postmenopausal women with severe osteoporosis at high fracture risk, romosozumab has steadily cemented its place in treatment guidelines.
With research continuing to validate and expand its benefits, the treatment represents not only a scientific breakthrough but also a strategic shift in how osteoporosis is managed on the global stage.
In summary
Romosozumab is proving to be more than a promising innovation – it is a game-changing solution backed by extensive data, both clinical and real-world.
From its dual-action mechanism to its long-term cost-effectiveness and growing first-line adoption, the treatment is redefining standards in osteoporosis care, offering renewed hope for patients and professionals alike.
News Credits: Global data highlights effectiveness of romosozumab
Things you may also like:
- Untamed Secures £10 Million to Expand Pet Food Empire Beyond DTC
- Lung Cancer Breakthrough: New Lab Technique Could Transform Treatment and Early Detection
- Lottie Shaw’s Sets Its Sights on Sweeter Horizons with Major Investment